Maintenance bacillus calmette-guérin: Why is there continued debate?

European Urology

Volumn 64, Issue 4, 2013, Pages 586-587

  Inman, Brant A ^a   Abern, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GEMCITABINE; MITOMYCIN;

BCG VACCINATION; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BCG VACCINE; HUMANS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84883761037     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.055     Document Type: Editorial

References (11)

1. G.H. Guyatt, A.D. Oxman, R. Kunz, G.E. Vist, Y. Falck-Ytter, and H.J. Schünemann What is "quality of evidence" and why is it important to clinicians? BMJ 336 2008 995 998
2. J.P. Ioannidis, A.B. Haidich, and M. Pappa Comparison of evidence of treatment effects in randomized and nonrandomized studies JAMA 286 2001 821 830
3. B. Ehdaie, R. Sylvester, and H. Herr Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence Eur Urol 64 2013 579 585
4. A. Bohle Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials Int Braz J Urol 28 2002 585 586
5. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6; discussion 686-7.
6. A. Bohle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95
7. R.F. Han, and J.G. Pan Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials Urology 67 2006 1216 1223
8. P.U. Malmstrom, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
9. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
10. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91; discussion 91-2.
11. J. Oddens, M. Brausi, and R. Sylvester Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472